A. Sidney Barritt, MD: Updating TARGET-NASH

December 21, 2020
Kenny Walter

Kenny Walter is an editor with HCPLive. Prior to joining MJH Life Sciences in 2019, he worked as a digital reporter covering nanotechnology, life sciences, material science and more with R&D Magazine. He graduated with a degree in journalism from Temple University in 2008 and began his career as a local reporter for a chain of weekly newspapers based on the Jersey shore. When not working, he enjoys going to the beach and enjoying the shore in the summer and watching North Carolina Tar Heel basketball in the winter.

The TARGET-NASH study seeks to shed light on treatment for NASH and NAFLD.

Researchers believe there might soon be a treatment for liver diseases such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

While there is currently not an approved treatment for these disorders, the TARGET-NASH study is designed to give researchers a better understanding on the characteristics of the disease, which may payoff in terms of treatments.

TARGET-NASH is an observational study of participants with NAFLD and/or NASH in usual clinical practice and is part of a series of Target studies targeted several diseases, including inflammatory bowel disease and asthma.

All of the patients have been diagnosed with NASH, either by their physician or by a biopsy.

In an interview with HCPLive®, A. Sidney Barritt IV, MD, MSCR, Associate Professor of Medicine, Division of Gastroenterology and Hepatology, Director, UNC Liver Center, explained how the TARGET-NASH trial will provide researchers with significantly more data on effective treatments for the conditions.

Barritt said there are currently more than 5000 patients enrolled from both academic centers and community centers in the trial since enrollment began in 2016.

The goal of the ongoing study is to get an unbiased view of the disease moving forward.


x